Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Disorders of Hemostasis01:24

Disorders of Hemostasis

918
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
918
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

330
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
330
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

7.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Enoxaparin, Tinzaparin, and Apixaban Modulate Cancer Cell Procoagulant Activity and Viability: Comparison with Quercetin.

Cancers·2026
Same author

'What' and 'How' to Measure in Allergy and Clinical Immunology: A Systematic Review of Core Outcome Sets and Outcome Harmonisation Processes.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Sex Differences in Cancer-Associated Thrombosis.

International journal of molecular sciences·2026
Same author

Structured exercise training and rehabilitation in patients with acute venous thromboembolism: a systematic review of randomized controlled trials.

European journal of preventive cardiology·2026
Same author

Catastrophic Antiphospholipid Syndrome.

Seminars in thrombosis and hemostasis·2026
Same author

Combined Oral Contraceptives and the Risk of Thrombosis.

International journal of molecular sciences·2025

相关实验视频

Updated: Jul 5, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

384

灾难性的抗脂综合征

Victoria Bitsadze1, Fidan Yakubova1, Jamilya Khizroeva1

  • 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children's Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str. 8-2, 119991 Moscow, Russia.

International journal of molecular sciences
|January 11, 2024
PubMed
概括

灾难性抗脂综合征 (CAPS) 涉及严重的微血栓和炎症. 及时诊断和跨学科护理,包括LMWH,对于改善CAPS患者的治疗结果和降低CAPS患者的死亡率至关重要.

关键词:
抗脂抗体是一种抗脂抗体.抗脂综合征是一种抗脂综合征.灾难性的抗脂蛋白综合征孕期并发症 孕期并发症

更多相关视频

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.7K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

568

相关实验视频

Last Updated: Jul 5, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

384
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.7K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

568

科学领域:

  • 免疫学 免疫学 免疫学
  • 血液学 血液学 血液学
  • 类风湿病学 类风湿病学

背景情况:

  • 灾难性抗脂综合征 (CAPS) 是一种罕见的,危及生命的疾病,其特征是广泛的微血栓形成.
  • 与经典的抗脂综合征 (APS) 不同,CAPS涉及一种被称为"血栓风暴"的严重炎症反应.
  • CAPS通常在感染,创伤或手术后出现,症状包括发烧,血栓塞缩症和多器官衰竭.

研究的目的:

  • 突出CAPS的诊断挑战,特别是反脂抗体水平的波动.
  • 概述目前用于管理CAPS的治疗策略.
  • 强调改善临床方案和医疗教育的必要性,以获得更好的患者结果.

主要方法:

  • 对CAPS的临床表现和诊断标准的审查.
  • 分析目前的治疗方式,包括三重疗法 (抗凝剂,血酶,葡萄糖皮质类固醇) 和LMWH.
  • 讨论CAPS的多因素性质和管理复杂性.

主要成果:

  • 抗脂抗体水平可能会波动,使CAPS诊断复杂化.
  • 三重疗法是一种常见的治疗方法,由于其抗炎和抗凝固特性,建议使用LMWH.
  • 有效的管理需要跨学科的方法,及时的诊断和预防策略.

结论:

  • CAPS需要专门的医疗护理和及时诊断,以减轻严重后果.
  • 改进的临床方案和教育对于改善治疗方法和降低CAPS相关死亡率至关重要.
  • 早期识别和管理是解决CAPS特征的"血栓风暴"的关键.